DrugPatentWatch Database Preview
NOVOLIN 70/30 Drug Profile
» See Plans and Pricing
Summary for Tradename: NOVOLIN 70/30
| Patents: | 5 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for NOVOLIN 70/30 |
Recent Clinical Trials for NOVOLIN 70/30
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| University of Illinois at Chicago | Phase 2 |
| State University of New York - Downstate Medical Center | Phase 4 |
| University of California, San Francisco | N/A |
Patent Text Search: US Patents for NOVOLIN 70/30
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc | NOVOLIN 70/30 | insulin recombinant human; insulin susp isophane recombinant human | INJECTABLE;INJECTION | 019991 | 001 | 1991-10-07 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2033-03-11 | Over-the-counter | search | |
| Novo Nordisk Inc | NOVOLIN 70/30 | insulin recombinant human; insulin susp isophane recombinant human | INJECTABLE;INJECTION | 019991 | 001 | 1991-10-07 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2029-05-13 | Over-the-counter | search | |
| Novo Nordisk Inc | NOVOLIN 70/30 | insulin recombinant human; insulin susp isophane recombinant human | INJECTABLE;INJECTION | 019991 | 001 | 1991-10-07 | Start Trial | INDIAN INSTITUTE OF TECHNOLOGY, BOMBAY (Mumbai, IN) | 2036-02-19 | Over-the-counter | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for NOVOLIN 70/30
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2017141262 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
